International Classification of Functioning, Disability and Health

NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

Retrieved on: 
Tuesday, September 26, 2023

Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.

Key Points: 
  • Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.
  • The publication , Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders, featured in the September 19th 2023 Frontiers in Pain Research, reviewed records of 101 adolescents treated with 4 weeks of IB-Stim™, amitriptyline or cyproheptadine.
  • In the study, 59% of patients in the IB-Stim group had failed prior standard medical therapy.
  • Dr. Adrian Miranda, Chief Medical Officer of NeurAxis, said, “It is exciting to see a comparative evaluation of IB-Stim™ with standard medical therapy.

NeurAxis Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, September 21, 2023

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the second quarter ended June 30, 2023.
  • Gross margin totaled 89.5% in the second quarter of 2023, compared to 88.4% in second quarter of 2022.
  • Selling expenses for the second quarter of 2023 were $78.8 thousand, compared to $127.4 thousand in the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $1,507.2 thousand, compared to $1,132.1 thousand in the second quarter of 2022.

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

Retrieved on: 
Tuesday, September 12, 2023

The publication , led by investigators from Children’s Hospital of Orange County, investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim.

Key Points: 
  • The publication , led by investigators from Children’s Hospital of Orange County, investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim.
  • The patients were treated for 4 weeks and data were collected prospectively from both the patient and the parents using validated questionnaires.
  • The global health scores also significantly improved based on both patient and parent reports (p
  • Dr. Adrian Miranda, Chief Medical Officer of NeurAxis said, “We are pleased that outcomes post IB-Stim treatment continue to be replicated at centers of excellence across the country.

Empowering Tomorrow's Healthcare Leaders: USAHS Sponsors 6th Annual U.S. Open Adaptive Surfing Championship

Retrieved on: 
Wednesday, August 30, 2023

OCEANSIDE, Calif., Aug. 30, 2023 /PRNewswire/ -- The anticipation is building as the 6th Annual U.S. Open Adaptive Surfing Championship approaches, slated to take place from September 6th to 10th at the iconic Oceanside Pier in Oceanside, California. Proudly sponsored by the University of St. Augustine for Health Sciences (USAHS) for the fourth consecutive year, this event not only showcases the incredible athleticism of adaptive surfers from around the world but also highlights the university's commitment to community support and hands-on education.

Key Points: 
  • OCEANSIDE, Calif., Aug. 30, 2023 /PRNewswire/ -- The anticipation is building as the 6th Annual U.S. Open Adaptive Surfing Championship approaches, slated to take place from September 6th to 10th at the iconic Oceanside Pier in Oceanside, California.
  • "The University of St. Augustine for Health Sciences is thrilled to once again be the title sponsor of the U.S. Open Adaptive Surfing Championship," said Dr. Mo Johnson, Assistant Professor of the Occupational Therapy Program at USAHS and Head of the International Classification for Para Surfing.
  • With over 100 athletes from more than 17 countries participating, the U.S. Open Adaptive Surfing Championship has evolved into an international gathering of champions.
  • For more information about the 6th Annual U.S. Open Adaptive Surfing Championship and the University of St. Augustine for Health Sciences, please visit https://usopenadaptivesurfingchampionships.com/ .

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

Retrieved on: 
Tuesday, August 22, 2023

Bacterial species in the Clostridiaceae family were more abundant in IBS patients compared to healthy control group.

Key Points: 
  • Bacterial species in the Clostridiaceae family were more abundant in IBS patients compared to healthy control group.
  • After treatment with IB-Stim, there were notable decreases in the clostridial species which have previously been implicated in gastrointestinal pro-inflammatory states.
  • Also, noted after treatment was a decrease in bacterial pathways of long-chain fatty acid synthesis, suggesting modulation of the microbiome and perhaps related inflammation.
  • According to the authors, “this suggests that patients with a specific microbial signature have a more favorable response to therapy.”2

Focused Ultrasound Treatment is Proven an Effective Treatment to Curb Tremor for at Least Five Years

Retrieved on: 
Thursday, July 20, 2023

HAIFA, Israel and MIAMI, July 20, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound (FUS) technology to transform patient care, today announced FDA approval of the five-year study endpoint for the largest prospective long-term, follow-up study of unilateral MR-guided focused ultrasound (MRgFUS) surgery (thalamotomy) for essential tremor (ET) to date. The data shows sustained and significant tremor improvement at five years with an overall improvement in quality-of-life measures and without any progressive or delayed complications. The study also confirms the long-term efficacy of the procedure for sufferers of ET, and follows the recent FDA approval of use of the technology to treat the second side tremor of appropriate patients. Insightec's Focused Ultrasound technology has been used to perform over 11,000 procedures worldwide.

Key Points: 
  • Insightec's Focused Ultrasound technology has been used to perform over 11,000 procedures worldwide.
  • "It also substantiates that using MR-guided focused ultrasound to treat essential tremor is safe and effective, as well as long-lasting.
  • We look forward to making further progress in finding more uses for focused ultrasound and building on the success of the treatment of essential tremor."
  • "Being part of the clinical study 7 years ago was life changing," says Alexandra Lebenthal, a clinical trial Focused Ultrasound patient from 2016.

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Retrieved on: 
Tuesday, May 16, 2023

NETANYA, Israel and BRIDGEWATER, N.J., May 16, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced the results of a recent study published in the Journal of Medical Economics, showing that Nerivio®, a novel Remote Electrical Neuromodulation (REN) wearable, provides significant cost savings in addition to clinical benefits when used as a preventive migraine treatment.

Key Points: 
  • The randomized, double-blind, placebo-controlled trial aimed to assess the clinical benefits and associated cost savings from use of REN with Nerivio for migraine prevention.
  • Participants treated with either Nerivio or a placebo device every other day for prevention of migraine.
  • Health insurance systems and employers should consider the powerful financial incentives that come with this drug-free migraine treatment."
  • Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Zynex, Inc. (ZYXI)

Retrieved on: 
Wednesday, March 29, 2023

The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).

Key Points: 
  • The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).
  • The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Zynex, through its subsidiary, markets electro therapy products, which help improve the quality of life of patients who have functional disabilities.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Zynex, Inc. (ZYXI)

Retrieved on: 
Friday, March 10, 2023

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).

Key Points: 
  • NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).
  • The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Zynex, through its subsidiary, markets electro therapy products, which help improve the quality of life of patients who have functional disabilities.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Zynex, Inc. (ZYXI)

Retrieved on: 
Wednesday, March 8, 2023

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).

Key Points: 
  • NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI ).
  • The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Zynex, through its subsidiary, markets electro therapy products, which help improve the quality of life of patients who have functional disabilities.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.